Design Therapeutics price target raised to $14 from $13 at RBC Capital

RBC Capital raised the firm’s price target on Design Therapeutics (DSGN) to $14 from $13 and keeps an Outperform rating on the shares after its Q4 results. The firm notes that the company remains on track with its two key programs – DT-216p2 for Friedreich’s ataxia and DT-168 in Fuchs Endothelial Corneal Dystrophy -with data for both expected in the second half of 2026, the analyst tells investors in a research note.